3-((4R,7S,10S,13S,16S,19R)-4-((S)-2-(((S)-6-amino-1-((carboxymethyl)amino)-1-oxohexan-2-yl)carbamoyl)pyrrolidine-1-carbonyl)-7-(2-amino-2-oxoethyl)-19-(2-(2-(2-aminoacetamido)acetamido)acetamido)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-10-yl)propanoic acid; [7-L-Glutamic acid,12-glycine]terlipressin; Glu(7), Gly(12)]-Terlipressin [Glu(7)-TLY-COOH]; (4-9-cyclo)-H-Gly-Gly-Gly-Cys-Tyr-Phe-Glu-Asn-Cys-Pro-Lys-Gly-OH
Terlipressin EP Impurity K (TFA Salt) is a fully characterized chemical compound used as a reference standard of API Terlipressin. The standard offered is compliant with regulatory guidelines. Terlipressin EP Impurity K (TFA Salt) is used for analytical method development, method validation (AMV), and Quality Controlled (QC) applications during synthesis and formulation stages of drug development and serves as a reference standard for traceability against pharmacopeial standards (USP or EP). Axios Research products are intended for analytical purposes only and are not for human use. CAS - NA
